Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Arif AkyildizDeniz Can GuvenBaris KoksalBeliz Bahar KaraoglanDerya KivrakRashad IsmayilovFirat AslanOsman SutcuogluOzan YaziciAhmet KadiogluOzkan AlanNargiz MajidovaMert ErciyestepeErkan OzcanGoncagul AkdagHakan TabanAli Osman KayaMurad GuliyevNilgun YildirimTeoman SakalarDogan YazilitasCaglar UnalSercan OnSedat BiterNebi Serkan DemirciFiliz Cay SenlerYasemin KemalOmer Diker HalilIbrahim GulluSercan AksoyPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024)
Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes.